KPTIHealthcare · BiotechnologyThe 5 Wall Street analysts covering Karyopharm Therapeutics, Inc. hold a median 12-month price target of $7.5 — +282.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 65 of 100 as at 22 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Karyopharm Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (94): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (4): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on KPTI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +282.7% from it.
Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 31 July 2026 | HC Wainwright & Co. | Downgrade | Neutral | $13 → $3.00 |
| 31 July 2026 | Piper Sandler | Maintains | Overweight | $16 → $7.00 |
| 6 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 6 May 2026 | HC Wainwright & Co. | Maintains | Buy | $8.00 → $13 |
| 27 Apr 2026 | Piper Sandler | Reiterates | Overweight | — |
| 30 Mar 2026 | Piper Sandler | Reiterates | Overweight | — |
| 25 Mar 2026 | Baird | Maintains | Outperform | — |
| 25 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 Mar 2026 | Rodman & Renshaw | Initiates | Buy | — |
| 18 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Feb 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 4 Nov 2025 | RBC Capital | Maintains | Outperform | — |
| 13 Oct 2025 | HC Wainwright & Co. | Upgrade | Buy | — |
| 9 Oct 2025 | Baird | Maintains | Outperform | — |
| 9 Oct 2025 | Piper Sandler | Reiterates | Overweight | — |
| 12 Aug 2025 | Baird | Maintains | Outperform | — |
| 16 July 2025 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 11 July 2025 | HC Wainwright & Co. | Assumes | Buy | $27 |
| 13 May 2025 | Baird | Maintains | Outperform | — |
| 13 May 2025 | Barclays | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KPTI appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 77% of US stocks
Cheaper than 90% of US stocks
Cheaper than 93% of US stocks
Cheaper than 76% of US stocks
Higher than 14% of US stocks
Higher than 55% of US stocks
Higher than 99% of US stocks
Higher than 15% of US stocks
Higher than 4% of US stocks
Higher than 94% of US stocks
Higher than 8% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Karyopharm Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Karyopharm Therapeutics held its Q2 2026 earnings call, and a transcript of the event has been published by Seeking Alpha.
Why it matters — Earnings-call transcripts provide investors with management's direct commentary on quarterly financial results and business outlook.
Karyopharm Therapeutics reported a Q2 loss of $2.32 per share, wider than the Zacks Consensus Estimate of a $1.53 loss but narrower than the $4.32 per share loss a year ago, while beating revenue estimates.
Why it matters — The wider-than-expected quarterly loss and revenue beat give KPTI watchers a current view of the company's financial performance against analyst expectations.
Karyopharm reported second quarter 2026 financial results, with total revenue of $33.4 million and U.S. XPOVIO (selinexor) net product revenue of $30.8 million. The company said its planned August sNDA submission for selinexor in combination with ruxolitinib in myelofibrosis under the accelerated approval pathway remains on track and reaffirmed its full-year 2026 total revenue guidance of $130 million to $150 million.
Why it matters — KPTI watchers would care because the myelofibrosis sNDA submission timing and revenue guidance confirm progress toward what could be the first approved combination therapy for myelofibrosis patients.
Karyopharm Therapeutics announced it will report its second quarter 2026 financial results on Thursday, August 13, 2026, before the market open, and will hold a conference call at 8:00 a.m. ET that same day. The announcement was issued from the company's Newton, Mass. headquarters.
Why it matters — This lets KPTI watchers know when to expect the company's next quarterly financial update and earnings call.
Karyopharm Therapeutics announced that it granted 333 restricted stock units (RSUs) to one newly-hired employee. The grant was reported under Nasdaq Listing Rule 5635(c)(4), which covers equity inducement awards for new employees.
Why it matters — KPTI watchers would care because the announcement reflects the company's equity-compensation activity for new hires, a routine corporate disclosure tracked by shareholders and Nasdaq-listed issuers.
The 5 Wall Street analysts covering Karyopharm Therapeutics, Inc. have a median 12-month price target of $7.5, with estimates ranging from $3 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Karyopharm Therapeutics, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Karyopharm Therapeutics, Inc. 65 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Karyopharm Therapeutics, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (94 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +282.7% from the last close, and Ticker Nerd's factor model ranks Karyopharm Therapeutics, Inc. 65 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Karyopharm Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KPTI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $11 over the next 12 months.
Karyopharm Therapeutics, Inc. returned -67.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Karyopharm Therapeutics Inc. is a commercial-stage biopharmaceutical company specializing in the discovery, development, and commercialization of innovative cancer therapies.
The most recent item we track (Seeking Alpha, 13 Aug 2026): "Karyopharm Therapeutics Inc. (KPTI) Q2 2026 Earnings Call Transcript". Karyopharm Therapeutics held its Q2 2026 earnings call, and a transcript of the event has been published by Seeking Alpha.
Karyopharm Therapeutics Inc. is a commercial-stage biopharmaceutical company specializing in the discovery, development, and commercialization of innovative cancer therapies. The company focuses on nuclear export inhibition, having developed small-molecule compounds that target exportin 1 (XPO1), a protein involved in intracellular communication between the nucleus and cytoplasm. The company's lead therapeutic product is XPOVIO (selinexor), which is approved in the United States for treating multiple hematologic malignancies, including multiple myeloma in combination with established therapies and relapsed or refractory diffuse large B-cell lymphoma as a monotherapy. Karyopharm operates primarily in the healthcare and biotechnology sectors, deriving revenue from the United States market. Headquartered in Newton, Massachusetts, the company remains dedicated to advancing novel cancer treatment options through its specialized platform targeting nuclear export mechanisms.
CEO Mr. Richard A. Paulson M.B.A. · 228 employees · United States · https://www.karyopharm.com